Atasin EZ 10/10 Tablet

About Atasin EZ 10/10 Tablet

Atasin EZ 10/10 is a tablet made by Advanced Chemical Industries PLC. It combines atorvastatin and ezetimibe, two lipid-lowering medicines, and is prescribed to help manage cholesterol levels.

There are 8 brands of Atorvastatin + Ezetimibe listed in Bangladesh.

What is Atasin EZ 10/10 Tablet?

Atasin EZ 10/10 is a tablet manufactured by Advanced Chemical Industries PLC. It contains atorvastatin and ezetimibe, two active ingredients that work in different ways to lower cholesterol. Atorvastatin reduces cholesterol production in the liver, while ezetimibe reduces cholesterol absorption from the intestine. This medicine is used as part of a broader plan that includes diet and other risk factor changes for people at increased risk of heart and blood vessel disease due to high cholesterol. The doctor decides the appropriate dose and course for each patient.

Uses of Atasin EZ 10/10

Atasin EZ 10/10 is used alongside diet to lower cholesterol in people at significantly increased risk of atherosclerotic vascular disease due to hypercholesterolemia. It is not a standalone treatment; it should be combined with multiple risk factor interventions. The doctor determines if this medicine is suitable based on individual health status and cholesterol levels.

How to use Atasin EZ 10/10

The doctor decides the dose and how often Atasin EZ 10/10 should be taken. The tablet is usually taken by mouth, but the exact schedule depends on the prescription. It may need to be taken at specific times relative to other medicines, such as bile acid sequestrants. Always follow the doctor's instructions and do not change the dose without consulting them.

Side effects of Atasin EZ 10/10

Like all medicines, Atasin EZ 10/10 can cause side effects, though not everyone experiences them. Patients should promptly report any unexplained or persistent muscle pain, tenderness, or weakness to the doctor, as these may be signs of muscle problems. Other side effects may occur; the doctor or pharmacist can provide a full list and advice on managing them.

Safety and precautions

Atasin EZ 10/10 is not for people with active liver disease, unexplained persistent liver enzyme elevations, or hypersensitivity to any ingredient. It is contraindicated during pregnancy and breastfeeding. Women who may become pregnant should use effective contraception and consult their doctor. Patients with risk factors such as advanced age, uncontrolled hypothyroidism, or kidney impairment should inform the doctor before starting this medicine. Report any muscle symptoms promptly.

Frequently asked questions

What kind of medicine is Atasin EZ 10/10 and what is it used for?

Atasin EZ 10/10 is a tablet containing atorvastatin and ezetimibe, two lipid-regulating medicines. It is used along with diet to lower cholesterol in people at increased risk of heart and blood vessel disease due to high cholesterol. The doctor decides if it is right for you.

What medicines may interact with Atasin EZ 10/10?

Atasin EZ 10/10 may interact with cyclosporine, certain HIV and hepatitis C protease inhibitors, gemfibrozil, clarithromycin, itraconazole, and other lipid-lowering medicines. Some combinations should be avoided or need dose adjustments. Always tell your doctor or pharmacist about all medicines you take, including over-the-counter products.

How should Atasin EZ 10/10 be taken?

The doctor decides the dose and how often you should take Atasin EZ 10/10. Follow the prescription exactly. The timing may need to be adjusted if you also take bile acid sequestrants. Do not change the dose or stop taking it without consulting your doctor.

Who should not take Atasin EZ 10/10?

Atasin EZ 10/10 is not suitable for people with active liver disease, unexplained persistent liver enzyme elevations, or allergy to any ingredient. It is also contraindicated during pregnancy and breastfeeding. Women who may become pregnant should use effective contraception and consult their doctor before taking this medicine.

Indications

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted ... Read moreTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.

Primary Hyperlipidemia: This tablet is indicated for the reduction of elevated total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia.

Homozygous Familial Hypercholesterolemia (HoFH): This tablet is indicated for the reduction of elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.

Pharmacology

Atorvastatin: In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles.

Ezetimibe
: Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. In a 2-week clinical study in 18 hypercholesterolemic patients, ezetimibe inhibited intestinal cholesterol absorption by 54%, compared with placebo. Ezetimibe had no clinically meaningful effect on the plasma concentrations of the fat-soluble vitamins A, D, and E and did not impair adrenocortical steroid hormone production. Ezetimibe does not inhibit cholesterol synthesis in the liver or increase bile acid excretion. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of statins.

Dosage & Administration

The dosage range is 10/10 mg/day through 80/10 mg/day. Recommended starting dose is 10/10 mg/day or 20/10 mg/day. Recommended starting dose is 40/10 mg/day for patients requiring a greater than 55% reduction in LDL-C.  Dosing of this tablet should occur either greater than or equal to 2 hours before or greater than or equal to 4 hours after administration of a bile acid sequestrant.

Interaction

  • Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir), gemfibrozil: Avoid this tablet
  • HIV protease inhibitor (lopinavir plus ritonavir): Use with caution and lowest dose necessary.
  • Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir): Do not exceed 10/20 mg this tablet daily.
  • HIV protease inhibitor (nelfinavir), hepatitis C protease inhibitor (boceprevir): Do not exceed 10/40 mg this tablet daily.
  • Other lipid-lowering medications: Use with fenofibrates or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with this tablet.
  • Fenofibrates: Combination increases exposure of ezetimibe. If cholelithiasis is suspected in a patient receiving ezetimibe and a fenofibrate, gallbladder studies are indicated and alternative lipid- lowering therapy should be considered.
  • Cholestyramine: Combination decreases exposure of ezetimibe.
  • Digoxin: Patients should be monitored appropriately.
  • Oral contraceptives: Values for norethindrone and ethinyl estradiol may be increased.
  • Rifampin should be simultaneously coadministered with this tablet.

Contraindications

  • Active liver disease or unexplained persistent elevations of hepatic transaminase levels.
  • Hypersensitivity to any component of this tablet.
  • Women who are pregnant or may become pregnant.
  • Nursing mothers.

Pregnancy & Lactation

Pregnancy Category X. This tablet is contraindicated in women who are or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy. Lipid-lowering drugs offer no benefit during pregnancy, because cholesterol and cholesterol derivatives are needed for normal fetal development. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy. It is not known whether atorvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk.

Precautions & Warnings

Patients should be advised to report promptly any unexplained and/or persistent muscle pain, tenderness, or weakness. This tablet should be discontinued immediately if myopathy is diagnosed or suspected.

Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase with higher doses and concomitant use of certain CYP3A4 inhibitors, fibric acid derivatives, and cyclosporine. Predisposing factors include advanced age (>65), uncontrolled hypothyroidism, and renal impairment. Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported.

Liver enzyme abnormalities: Persistent elevations in hepatic transaminase can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Alternative brands of Atorvastatin + Ezetimibe

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.